Two widely prescribed statin medications may be associated with a higher long-term risk of erectile dysfunction (ED), according to a study by Chinese researchers. The findings suggest that atorvastatin and simvastatin could increase this risk more than another common statin, rosuvastatin.
Statins are cholesterol-lowering drugs taken by millions globally to maintain healthy blood vessels and reduce the risk of heart attacks and strokes. In the UK alone, approximately eight million adults are prescribed these medications. Concurrently, erectile dysfunction affects around half of men over 40 in the UK.
The link between statins and ED has been a subject of varied research. Some studies have proposed that statins could improve ED by enhancing blood flow, while others suggest a potential negative impact due to reduced cholesterol levels, which are necessary for testosterone production.
This latest research, conducted by scientists at the Sixth Hospital of Wuhan, analyzed genetic data from over 223,000 individuals, including more than 6,000 men diagnosed with ED, utilizing data from the UK Biobank and Finland's FinnGen project. The analysis aimed to estimate the long-term effects of statin use.
Overall, the study indicated a 6.4% increase in the risk of ED associated with statin use, with atorvastatin and simvastatin identified as the primary drivers of this increased risk. Atorvastatin is widely recognized by its brand name Lipitor, and simvastatin by Zocor. These are among the statins prescribed in Britain, alongside rosuvastatin (Crestor), pravastatin (Lipostat), and fluvastatin (Lescol).
Researchers hypothesize that the difference in risk might stem from how these statins are distributed within the body. Atorvastatin and simvastatin may more readily reach the testicles, potentially impacting testosterone production. Rosuvastatin, conversely, tends to remain primarily in the liver, with a lower likelihood of reaching the testicles, which could explain the absence of a link to ED in this study. The researchers also proposed that statins that more aggressively lower cholesterol might leave insufficient amounts for the body to produce essential hormones like testosterone.
Authors of the study cautioned that the findings should be interpreted with care. They emphasized that the study estimates the potential effects of lifelong statin exposure, rather than the risks associated with typical clinical use. While the results offer evidence supporting a connection, they advised against causing unnecessary alarm or prompting individuals to discontinue their medication without consulting a healthcare professional. Clinicians were advised to monitor the sexual health of patients using statins, and switching to rosuvastatin was suggested as a potential strategy for those experiencing ED.